Quality of life and survival with continuous hepatic-artery @entity10049 infusion for XXXX .

@entity1 @entity308 @entity648 @entity5906 @entity10049 @entity148 @entity14 @entity3
Very few @entity1 with liver metastases from @entity14 can be cured. We have investigated whether a treatment to slow the growth of liver metastases, hepatic-artery infusion of @entity10049 , improves palliation in this setting. In a randomised study of 100 @entity1 , we compared quality of life and survival in @entity1 who received hepatic-artery infusion of @entity10049 and in those who received conventional symptom palliation. 95% of control @entity1 survival time was spent with normal quality-of-life scores, which suggests that the aim of treatment should be to prolong normal-quality survival rather than merely to sustain quality of life. There was a significant prolongation (p = 0.03) in overall survival in @entity10049 -treated @entity1 compared with controls (median 405 vs 226 days). There were similar significant prolongations in normal-quality (ie, normal symptom scores) survival for physical symptoms (p = 0.04), @entity148 (p = 0.04), and @entity308 (p = 0.04). This survival benefit was associated with significant reductions in @entity3 size on computed tomography (p = 0.001) and in serum carcinoembryonic antigen concentration (p = 0.006) in @entity10049 -treated @entity1 . There was no evidence of treatment-related hepatotoxicity as assessed by serum @entity5906 aminotransferase and @entity648 measurements. This is the first demonstration that survival can be prolonged with normal quality of life in @entity1 with @entity14 . We conclude that hepatic-artery @entity10049 infusion can be recommended for suitable @entity1 .
